Invitation to 2cureX Strategy Deep-Dive:

 

Market developments and strategic progress in functional drug sensitivity testing

 

The market for functional drug sensitivity testing is gaining in importance and recognition. Having launched three CE-marked IVD tests for colorectal cancer and developed a distributor network covering 17 countries in Europe and the Middle East, 2cureX is perfectly poised to take advantage of that situation, even considering the tough multi-faceted crisis we are living nowadays.

 

On Tuesday 15 November at 1:00 PM, 2cureX will be organising a Strategy Deep-Dive to discuss the company’s current position and its ongoing strategy. With promising results from a recent market survey, and the deep understanding of the (path to) market we have gained over the last 12 months, our management team and other experts are excited to provide an update of where we stand and where we are heading.

 

Topics will include:

• A clear description of 2cureX’s ongoing strategy
• The market opportunity in colorectal cancer
• Feedback from the market
• Status of the execution of our strategy